Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers

PURPOSE: Glasdegib is being developed for indications in myeloid malignancies. The effect of renal impairment on the pharmacokinetics (PK) of a single, oral, 100-mg glasdegib dose under fasted conditions was assessed. METHODS: Open-label, parallel-group study (NCT03596567). Participants of good gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaik, Naveed, LaBadie, Robert R., Hee, Brian, Chan, Geoffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870595/
https://www.ncbi.nlm.nih.gov/pubmed/33388951
http://dx.doi.org/10.1007/s00280-020-04207-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870595/
https://www.ncbi.nlm.nih.gov/pubmed/33388951
http://dx.doi.org/10.1007/s00280-020-04207-9

Ejemplares similares